Silverarc Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Silverarc Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-248,347	Closed	-$1.69M	–	87
2022 Q1	$1.69M	Buy	248,347 +2,518	+1%	+$17.9K	0.7%	35
2021 Q4	$2.05M	Buy	245,829 +37,270	+18%	+$307K	0.83%	39
2021 Q3	$1.55M	Sell	208,559 -42,085	-17%	-$261K	0.88%	41
2021 Q2	$1.7M	Sell	250,644 -99,356	-28%	-$825K	0.76%	48
2021 Q1	$3.6M	Sell	350,000 -56,665	-14%	-$621K	1.96%	17
2020 Q4	$2.85M	Buy	+406,665	New	+$3.17M	1.65%	22

Other funds holding JNCE

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Silverarc Capital Management's JNCE Position: Q2 2022 in Review

Silverarc Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 248,347 shares — an estimated $1.69M sold.

Silverarc Capital Management first reported a position in JNCE in Q4 2020 and held it in 6 quarters. The position peaked at $3.6M in Q1 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

Silverarc Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Silverarc Capital Management sold 248,347 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1.69M.
Silverarc Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Silverarc Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $3.6M in Q1 2021.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Silverarc Capital Management's 13F filing for Q2 2022, filed 25 Jul 2022.